←Back to list

OpenEvidence

AI copilot for doctors that synthesizes peer-reviewed medical evidence at the point of care
OpenEvidence is a Miami-based clinical AI company often called the 'ChatGPT for doctors' — its copilot synthesizes peer-reviewed medical literature into instantaneous, citation-backed answers at the point of care. Founded in 2021 by Kensho founder Daniel Nadler, it closed a $250M Series D in January 2026 co-led by Thrive Capital and DST Global at a $12B valuation, doubling from $6B six months earlier. Sacra estimates 2025 revenue at $150M, up over 1,800% YoY, with widespread adoption among U.S. physicians.
Healthcare 📍 Miami, FL Founded 2021
Current Valuation
$15B
as of 2026-09-24
DECACORN

QL Price

$15B
-2% vs last round
QuantLogix's current estimate for OpenEvidence, published 2026-10-08 — in line with the last disclosed round of $15B (2026-09-24).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round $15B 2026-09-24 weight 0.97
Secondary market print $14B 2026-06-27 weight 0.54
How this price has held up
No round has priced for OpenEvidence since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-08 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to OpenEvidence →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, OpenEvidence, 2026-10-08 (d2f932f6029927cd). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is OpenEvidence going public?
No. OpenEvidence is private and has not filed to go public. There is no S-1 on file.
What is OpenEvidence's valuation in 2026?
OpenEvidence is valued at $15B as of 09/24/2026, set by its Unlabeled (reported) ($250M, Sep 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has OpenEvidence filed an S-1?
No public S-1 is on file for OpenEvidence.
Who are OpenEvidence's investors?
OpenEvidence's investors include Thrive Capital, DST Global, Sequoia Capital, Kleiner Perkins, Coatue, Google Ventures and 2 more.
How much has OpenEvidence raised?
OpenEvidence has raised $950M in total across 2 disclosed rounds, most recently a Unlabeled (reported) of $250M in Sep 2026.
Is OpenEvidence publicly traded — can you buy OpenEvidence stock?
No. OpenEvidence is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for OpenEvidence on its Pre-IPO Access Desk.
How to actually get exposure to OpenEvidence →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

CEO
Daniel Nadler
Founded
2021
HQ
Miami, FL
Employees
~80
Total Raised
$950M
Est. Revenue
$150M (2025)
Growth
+1,803% YoY revenue growth (Sacra)
Last Round
Unlabeled (reported) — $250M (Sep 2026)
IPO Status
private

Fundraising Status

Unlabeled (reported) · $250M · 1 mo ago
privateTotal raised $950M2 disclosed rounds

Unlabeled (reported) Impact

Round Size
$250M
Primary financing announced
Post-Money Valuation
$15B
Company-announced mark
Valuation Step-Up
+25.0%
vs Series D at $12B
Round / Post-Money
1.7%
New capital ÷ post-money
Disclosed Funding
$950M
Cumulative disclosed rounds
Step-up compares disclosed post-money valuations. Round / post-money is a financing-size ratio, not an ownership or dilution estimate.

Secondary Market

Implied price / share
$454.21
Last round price / share
$487.38
vs last round
-6.8%
Open interest
14
Last round price vs secondary price
Last round vs current secondary price per share$487Last round$454Current
Secondary price return by period
Secondary market period returns3-month-11.4%6-month+78.5%1-year+45321%All-time+45321%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Growth & Valuation

Valuation across funding rounds
Valuation growth across funding rounds$12B$15BJan '26Sep '26
Capital raised per round
Capital raised per funding round$250MSeries D$250MUnlabeled (reported)
Charts built from publicly disclosed funding rounds and revenue estimates. Approximate, not real-time, not investment advice.

Funding History

RoundAmountDateLead InvestorPost-Money
Unlabeled (reported)$250MSep 2026—$15B
Series D$250MJan 2026Thrive Capital / DST Global (co-led)$12B

Vertical Intelligence — AI / ML

Open models
0
Downloads (30d)
0
across all models
Followers
26
Attributed to Hugging Face organization "OpenEvidence" as of 2026-10-04. Open-weights footprint only — closed-model usage is not publicly measurable. Verify on Hugging Face ↗

Talent Signal

Hiring trend
▲ Hiring uptrend
+14% vs 2026-08
Open roles
8
via ashby
Product-build share
75%
engineering, research, product, design
Trajectory
expanding
heavy product build — 75% of open roles are product-building functions (engineering/research/product) — 2 of 8 open roles are engineering.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by month7Aug '268Sep '26
Open roles by function
Open roles by functionEngineering2Research2Other1Data & ML1Security1Sales & GTM1
■ product-building   ■ go-to-market / G&A
Software Engineer, Data PlatformSoftware Engineer, Backend and InfrastructureSecurity Engineer, Platform Security Software Engineer, Site ReliabilityResearch ScientistSoftware Engineer, Applied AI
Counted from OpenEvidence's live job board as of 2026-09-15; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.

Founders & Key People

Daniel NadlerZachary Ziegler

Investors

Thrive Capital · DST Global · Sequoia Capital · Kleiner Perkins · Coatue · Google Ventures · Andreessen Horowitz · Nvidia

Products

  • OpenEvidence Clinical AI Copilot
  • Point-of-Care Evidence Search
  • Specialty-Specific Knowledge Graphs
  • EHR-Integrated Decision Support

Competitors

UpToDate (Wolters Kluwer) · DynaMed · Hippocratic AI · Abridge · Glass Health
AIHealthcareClinical Decision SupportMedical AI
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-09-24. Refreshed quarterly.